Sector Expert: André Uddin

Research Capital Corporation

Image: André Uddin

Andre Uddin is managing director, healthcare research at Mackie Research. Uddin has over 20 years of global experience in the investment, biotechnology and pharmaceutical industries, most recently as strategic advisor and consultant to a number of leading TSX and LSE companies. He was also Vice-President of Strategic Development for a NASDAQ-listed biopharmaceutical company. Uddin began his career in the brokerage community, where he was a top-ranked analyst specializing in coverage of the Canadian biotechnology, pharmaceutical and medical device sectors at National Bank Financial, Research Capital and Merrill Lynch Canada. Uddin holds an Honours Bachelor of Science in Biochemistry from the University of Toronto, and a Ph.D in Biological Chemistry from McGill University. Uddin's bio-organic research has been widely published in many scientific journals, including the Journal of American Chemical Society, Biochemistry and Nucleic Acid Research.



Recent Quotes

"AGN is switching focus to the IPF/chronic cough indication."

— André Uddin, Research Capital Corporation (8/4/21)
more >

"AGN requested a meeting with the FDA to discuss advancing ifenprodil."

— André Uddin, Research Capital Corporation (5/10/21)
more >

"Final results from AGN's Phase 2b COVID-19 trial are expected soon."

— André Uddin, Research Capital Corporation (3/1/21)
more >

"AGN is to continue a number of preclinical studies of DMT for stroke."

— André Uddin, Research Capital Corporation (2/2/21)
more >

"AGN remains a high risk, high reward investment opportunity."

— André Uddin, Research Capital Corporation (12/15/20)
more >

"We are initiating coverage of AGN with a Speculative Buy recommendation; its lead product, ifenprodil, is being repurposed for COVID-19, idiopathic pulmonary fibrosis (IPF) and chronic cough."

— André Uddin, Research Capital Corporation (8/19/20)
more >

"Multiple players are at the table with PMN for a licensing deal."

— André Uddin, Research Capital Corporation (3/21/19)
more >

"PMN is to initiate a Phase 1 PMN310 study for Alzheimer's in H2/19."

— André Uddin, Research Capital Corporation (3/15/19)
more >



Due to permission requirements, not all quotes are shown.